Loading patent…
AssigneeThe Brigham and Women's Hospital, Inc.
InventorsRichard S. Blumberg, Kristi Baker, Michal Pyzik, Amit Gandhi
Estimating the term…
As demonstrated herein, soluble human FcRn binds to AFP with affinities greater than observed with albumin, and is able to interfere with FcRn-mediated protection of and functional associations with IgG. Accordingly, provided herein, in some aspects, are compositions and methods to inhibit FcRn and AFP interactions in diseases or disorders where elevated AFP levels are associated with immunosuppression. Also provided herein, in some aspects, are compositions and methods to enhance or potentiate FcRn and AFP interactions in diseases or disorders with decreased AFP levels or diseases or disorders where increasing AFP levels increasing with immunosuppression.
A method to inhibit or reduce FcRn and alpha-fetoprotein (AFP) interactions in a disease or disorder associated with elevated AFP levels comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising an inhibitor of AFP-FcRn and a pharmaceutically acceptable carrier, wherein said inhibitor of AFP-FcRn inhibits binding between alpha-fetoprotein (AFP) and FcRn, wherein the inhibitor of AFP-FcRn inhibits or blocks the AFP binding site on FcRn, wherein the inhibitor of AFP-FcRn is an antibody or antigen-binding fragment thereof, wherein the inhibitor of AFP-FcRn is an anti-FcRn ADM31 antibody, and wherein the subject has or has been diagnosed with cancer.
A method to inhibit or reduce FcRn and alpha-fetoprotein (AFP) interactions in a disease or disorder associated with elevated AFP levels comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising an inhibitor of AFP-FcRn and a pharmaceutically acceptable carrier, wherein said inhibitor of AFP-FcRn inhibits binding between alpha-fetoprotein (AFP) and FcRn, wherein the inhibitor of AFP-FcRn inhibits or blocks the AFP binding site on FcRn, wherein the inhibitor of AFP-FcRn is an antibody or antigen-binding fragment thereof, wherein the inhibitor of AFP-FcRn is a chimeric anti-FcRn ADM31 antibody or a humanized anti-FcRn ADM31 antibody, and wherein the subject has or has been diagnosed with cancer.
Dependencies are inferred from the claim text.